A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy resulted in a significant and clinically meaningful improvement in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients ...

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

A recently completed phase 3 clinical trial, conducted by researchers at Mass General Brigham and collaborators, shows that combining inavolisib with palbociclib and fulvestrant improves overall ...

The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...